RT Journal Article
T1 Pulmonary long-term consequences of COVID-19 infections after hospital discharge.
A1 Blanco, Jose-Ramon
A1 Cobos-Ceballos, Maria-Jesus
A1 Navarro, Francisco
A1 Sanjoaquin, Isabel
A1 Arnaiz de Las Revillas, Francisco
A1 Bernal, Enrique
A1 Buzon-Martin, Luis
A1 Viribay, Miguel
A1 Romero, Lourdes
A1 Espejo-Perez, Simona
A1 Valencia, Borja
A1 Ibañez, David
A1 Ferrer-Pargada, Diego
A1 Malia, Damian
A1 Gutierrez-Herrero, Fernando-Gustavo
A1 Olalla, Julian
A1 Jurado-Gamez, Bernabe
A1 Ugedo, Javier
K1 COVID-19
K1 Intracellular adhesion molecule
K1 Lung diffusion capacity
K1 Osteoprotegerin
K1 Plasminogen activator inhibitor
K1 Tissue inhibitor of matrix metalloproteinases
K1 Tomography
AB Coronavirus disease 2019 (COVID-19) survivors are reporting residual abnormalities after discharge from hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. This study aimed to describe lung function in patients recovering from COVID-19 hospitalization and to identify biomarkers in serum and induced sputum samples from these patients. Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by a real-time PCR (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited for this study. Each hospital screened their lists of discharged patients at least 45 days after symptom onset. SARS-CoV-2-infected patients were divided into mild/moderate and severe disease groups according to the severity of their symptoms during hospitalization. Patients' epidemiological and medical histories, comorbidities, chronic treatments, and laboratory parameters were evaluated. Pulmonary function tests, the standardized 6-minute walk test (6MWT) and chest computed tomography (CT) were also performed. The levels of proteases, their inhibitors, and shed receptors were measured in serum and induced sputum samples. A total of 100 patients with respiratory function tests were included in this study. The median number of days after the onset of symptoms was 104 (IQR 89.25, 126.75). COVID-19 was severe in 47% of patients (47/100). CT was normal in 48% of patients (48/100). Lung function was normal forced expiratory volume in one second (FEV1) ≥80%, forced vital capacity (FVC) ≥80%, FEV1/FVC ≥0.7, and diffusing capacity for carbon monoxide (DLCO) ≥80% in 92% (92/100), 94% (94/100), 100% (100/100) and 48% (48/100) of patients, respectively. Multivariate analysis showed that a DLCO  A diffusion deficit (DLCO<80%) was still present after hospital discharge and was associated with the most severe SARS-CoV-2 cases
PB Elsevier
YR 2021
FD 2021-02-18
LK http://hdl.handle.net/10668/17272
UL http://hdl.handle.net/10668/17272
LA en
NO Blanco JR, Cobos-Ceballos MJ, Navarro F, Sanjoaquin I, Arnaiz de Las Revillas F, Bernal E, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect. 2021 Jun;27(6):892-896
DS RISalud
RD Apr 5, 2025